Zimmer Biomet (NYSE:ZBH) Stock Gets Price Target Boost from Stifel Nicolaus

Zimmer Biomet (NYSE:ZBH – Get Free Report) had its price objective upped by investment analysts at Stifel Nicolaus from $125.00 to $140.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Stifel Nicolaus‘s price objective would indicate a potential upside of 35.68% from the stock’s previous close.

ZBH has been the subject of a number of other reports. JPMorgan Chase & Co. raised their price target on Zimmer Biomet from $117.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, November 5th. Canaccord Genuity Group boosted their price objective on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Barclays increased their target price on Zimmer Biomet from $100.00 to $115.00 and gave the stock an “equal weight” rating in a research note on Monday, November 9th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $113.53.

View Our Latest Analysis on Zimmer Biomet

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $103.18 on Monday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.79. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $112.54. The firm has a market capitalization of $19.53 billion, a P/E ratio of 26.12, a price-to-earnings-growth ratio of 2.42 and a beta of 0.50. The company’s 50-day moving average is $95.76 and its 200 day moving average is $92.57.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.90 earnings per share. Research analysts forecast that Zimmer Biomet will post 8.56 EPS for the current year.

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The SEC filing for this sale provides additional information. 1.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of institutional investors and hedge funds have recently bought and sold shares of ZBH. BlackRock Inc. bought a new position in shares of Zimmer Biomet during the 2nd quarter worth $1,344,282,000. State Street Corp increased its stake in shares of Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after buying an additional 52,044 shares during the period. Primecap Management Co. CA purchased a new position in shares of Zimmer Biomet during the second quarter valued at $328,578,000. Dimensional Fund Advisors LP raised its holdings in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after acquiring an additional 24,208 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of Zimmer Biomet in the second quarter valued at about $187,480,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

See Also

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.